About Kritika Sarmah

Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.


Recent Articles By Kritika Sarmah

: KO |  News, Ratings, and Charts

Coca-Cola (KO) Earnings Analysis: Is Now the Time to Buy?

Coca-Cola (KO) just announced its first-quarter results, defying expectations with solid earnings. However, let us examine its performance, segment dynamics, and financial outlook to determine whether now is the opportune moment to buy into this beverage titan...
: ALNY |  News, Ratings, and Charts

4 Biotech Stocks to Watch Closely in May

With soaring drug demand and the recent inauguration of the National Bioeconomy Board, the biotech sector in the U.S. stands as an attractive investment opportunity. So, fundamentally strong biotech stocks Akebia Therapeutics (AKBA), Organogenesis Holdings (ORGO), Alnylam Pharmaceuticals (ALNY), and G1 Therapeutics (GTHX) might be ideal additions to one’s watchlist in May. Read more...
: MA |  News, Ratings, and Charts

Mastercard (MA) Earnings Forecast: Worth a Closer Look?

Payment power Mastercard (MA) is set to announce its first-quarter earnings result on May 1st. As investors eagerly await this financial update, let us analyze the company's recent performance and strategic initiatives to gauge its potential...
: XOM |  News, Ratings, and Charts

Exxon Mobil (XOM) Earnings Analysis: Ideal Time to Buy?

While the energy sector demonstrated resilience last year, falling natural gas prices could pose challenges this year. Industry leader Exxon Mobil (XOM) recently released its earnings, which paints an unclear picture. Let's analyze and find out if now could be an ideal time to buy the stock. Read on to find out...
: GOOGL |  News, Ratings, and Charts

GOOGL Earnings Breakdown and Optimizing Your Portfolio Strategy

With Alphabet's (GOOGL) earnings drawing near, investors eagerly await the potential earnings from its key services like Google Search, YouTube ad revenue, and Google Cloud. Join us as we delve into GOOGL's performance, offering insights to fine-tune your portfolio strategy...
: MSFT |  News, Ratings, and Charts

Will MSFT Add Value to Your Watchlist During Earnings?

As Microsoft (MSFT) gears up to announce its earnings on April 25, investors are eagerly awaiting to see if the tech giant will continue to impress. Despite its robust emphasis on cloud services and strategic AI investments, MSFT's recent downturns in personal and gaming revenues have sparked concerns. Is MSFT poised to enhance your watchlist with its upcoming earnings report? Let's explore...
: META |  News, Ratings, and Charts

Is META Preparing for Market Momentum?

Anticipation is high in the market this week as investors look forward to Meta Platforms (META) unveiling its first-quarter results on Wednesday, April 24th. With bullish analysts' estimates and historic announcements, could META be on the verge of market momentum? Let us find out...
: SCHW |  News, Ratings, and Charts

Does Charles Schwab's (SCHW) Q1 Performance Suggest a Buying Opportunity?

The first-quarter performance of The Charles Schwab Corporation (SCHW) has attracted considerable investor attention. But what lies beneath the surface? Let's dissect its fundamentals to ascertain whether it presents an enticing buying opportunity amidst today's market intricacies...
: TSM |  News, Ratings, and Charts

NVIDIA (NVDA) vs. Taiwan Semiconductor (TSM) - Which Chip Stock Will Dominate in Q2?

As technological advancements and investments increase, the chip industry anticipates significant benefits. While industry giants NVIDIA (NVDA) and Taiwan Semiconductor Manufacturing Company (TSM) are poised to capitalize on industry tailwinds, let's analyze which of these stocks is set for success in the second quarter...
: SGIOY |  News, Ratings, and Charts

3 Biotech Stocks to Buy to Power Through April

The biotech sector is primed for growth, fueled by a surge in FDA approvals, anticipated M&A deals, and the integration of AI in drug discovery. So, fundamentally sound biotech stocks Theratechnologies (THTX), Harmony Biosciences (HRMY), and Shionogi & Co. (SGIOY) might be solid buys in this month. Keep reading...
Page generated in 1.4318 seconds.